{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:58:06Z","timestamp":1785491886253,"version":"3.56.0"},"reference-count":43,"publisher":"American Association for Cancer Research (AACR)","issue":"6","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP170067"],"award-info":[{"award-number":["RP170067"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015725","name":"Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy","doi-asserted-by":"publisher","award":["101739"],"award-info":[{"award-number":["101739"]}],"id":[{"id":"10.13039\/100015725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Many of the &amp;gt;130 World Health Organization\u2013defined sarcoma subtypes are chemoresistant. To identify drug candidates with potential for repurposing in sarcomas with unmet needs, we screened structurally diverse small molecules across 20 sarcoma cell lines of various histologies. The screen included 1,387 compounds from the Custom Clinical Collection, NCI-Approved Oncology Set IV, and Selleck Bioactive Collection. The most effective agents were microtubule inhibitors, aurora kinase inhibitors, and heat shock protein inhibitors. Differential drug sensitivity was observed by sarcoma subtype. Ewing sarcoma, for example, was sensitive to aurora kinases and to TORIN-2 (an mTOR inhibitor). In contrast, myxoid liposarcoma and synovial sarcomas exhibited marked sensitivity to SNS-032, a CDK2\/7\/9 inhibitor identified by our screen. Interestingly, SNS-032 abrogates the downstream YAP pathway, a known driver pathway in the growth of these histotypes. Therefore, similar drug responses across histologies may indicate shared driver pathways and vulnerabilities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Sarcoma cells are resistant to most compounds that are currently approved for treating various diseases. Ewing sarcoma cells have distinct sensitivities to aurora kinases that can be explored, whereas myxoid liposarcoma and synovial sarcoma cells share similar drug sensitivity fingerprints that could be exploited in future basket trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0142","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T13:16:43Z","timestamp":1779369403000},"page":"1425-1434","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug Screening of Sarcoma Cells: Finding Shared Sensitivities"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5078-534X","authenticated-orcid":false,"given":"Hannah C.","family":"Beird","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Genomic Medicine, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6438-6561","authenticated-orcid":false,"given":"Carl","family":"Ho","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Genomic Medicine, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5490-5900","authenticated-orcid":false,"given":"Roberto","family":"Cardenas-Zuniga","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 2 Sarcoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6537-5551","authenticated-orcid":false,"given":"Asmaa","family":"Ahmed","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 2 Sarcoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3279-2209","authenticated-orcid":false,"given":"Clement","family":"Agyemang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 2 Sarcoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3200-1297","authenticated-orcid":false,"given":"Danh D.","family":"Truong","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 2 Sarcoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8634-2893","authenticated-orcid":false,"given":"Kevin","family":"Murgas","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 2 Sarcoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0657-6484","authenticated-orcid":false,"given":"Clifford C.","family":"Stephan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01tx6pn92","id-type":"ROR","asserted-by":"publisher"}],"name":"Texas A&M Health Science Center 3 High-Throughput Research and Screening Center, Center for Translational Cancer Research, , Institute of Biosciences and Technology, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6642-7777","authenticated-orcid":false,"given":"Yong Sung","family":"Park","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01tx6pn92","id-type":"ROR","asserted-by":"publisher"}],"name":"Texas A&M Health Science Center 3 High-Throughput Research and Screening Center, Center for Translational Cancer Research, , Institute of Biosciences and Technology, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6242-8315","authenticated-orcid":false,"given":"Reid T.","family":"Powell","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01tx6pn92","id-type":"ROR","asserted-by":"publisher"}],"name":"Texas A&M Health Science Center 3 High-Throughput Research and Screening Center, Center for Translational Cancer Research, , Institute of Biosciences and Technology, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8536-0812","authenticated-orcid":false,"given":"Joseph","family":"Tym","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/043jzw605","id-type":"ROR","asserted-by":"publisher"}],"name":"The Institute of Cancer Research 4 , London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9044-5510","authenticated-orcid":false,"given":"Sharon M.","family":"Landers","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 5 Surgical Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3560-5782","authenticated-orcid":false,"given":"Stephanie","family":"Schmidt","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Genomic Medicine, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6866-1484","authenticated-orcid":false,"given":"Noha M.","family":"Osman","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 5 Surgical Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1223-6542","authenticated-orcid":false,"given":"Dejka M.","family":"Araujo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 2 Sarcoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6232-1163","authenticated-orcid":false,"given":"Anthony P.","family":"Conley","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 2 Sarcoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0146-7732","authenticated-orcid":false,"given":"Neeta","family":"Somaiah","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 2 Sarcoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3367-2519","authenticated-orcid":false,"given":"Bissan","family":"Al-Lazikani","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Genomic Medicine, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6631-8554","authenticated-orcid":false,"given":"Joseph A.","family":"Ludwig","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 2 Sarcoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8663-2671","authenticated-orcid":false,"given":"Andrew","family":"Futreal","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Genomic Medicine, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"2026073105070036000_bib1","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1158\/1535-7163.MCT-15-0074","article-title":"Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression","volume":"14","author":"Teicher","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"2026073105070036000_bib2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41416-018-0359-4","article-title":"Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas","volume":"120","author":"Brodin","year":"2019","journal-title":"Br J Cancer"},{"key":"2026073105070036000_bib3","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.stem.2024.08.010","article-title":"The landscape of drug sensitivity and resistance in sarcoma","volume":"31","author":"Al Shihabi","year":"2024","journal-title":"Cell Stem Cell"},{"key":"2026073105070036000_bib4","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/labinvest.2016.64","article-title":"Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation","volume":"96","author":"de Graaff","year":"2016","journal-title":"Lab Invest"},{"key":"2026073105070036000_bib5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1023\/A:1006623001465","article-title":"A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies","volume":"17","author":"Jia","year":"1999","journal-title":"Clin Exp Metastasis"},{"key":"2026073105070036000_bib6","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/labinvest.2010.185","article-title":"An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors","volume":"91","author":"Peng","year":"2011","journal-title":"Lab Invest"},{"key":"2026073105070036000_bib7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/cancers12010141","article-title":"Mutant IDH1 depletion downregulates integrins and impairs chondrosarcoma growth","volume":"12","author":"Li","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026073105070036000_bib8","doi-asserted-by":"crossref","first-page":"14832","DOI":"10.18632\/oncotarget.4024","article-title":"The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo","volume":"6","author":"Suijker","year":"2015","journal-title":"Oncotarget"},{"key":"2026073105070036000_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J Biomol Screen"},{"key":"2026073105070036000_bib10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1087057105285611","article-title":"The minimum significant ratio: a statistical parameter to characterize the reproducibility of potency estimates from concentration-response assays and estimation by replicate-experiment studies","volume":"11","author":"Eastwood","year":"2006","journal-title":"J Biomol Screen"},{"key":"2026073105070036000_bib11","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1093\/bioinformatics\/btx364","article-title":"UpSetR: an R package for the visualization of intersecting sets and their properties","volume":"33","author":"Conway","year":"2017","journal-title":"Bioinformatics"},{"key":"2026073105070036000_bib12","article-title":"pheatmap: pretty heatmaps","author":"Kolde","year":"2025"},{"key":"2026073105070036000_bib13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","article-title":"The present and future of the Cancer Dependency Map","volume":"25","author":"Arafeh","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"2026073105070036000_bib14","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"},{"key":"2026073105070036000_bib15","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1038\/s41467-025-58678-6","article-title":"Genomic, transcriptomic, and immunogenomic landscape of over 1300 sarcomas of diverse histology subtypes","volume":"16","author":"Soupir","year":"2025","journal-title":"Nat Commun"},{"key":"2026073105070036000_bib16","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.1182\/blood-2008-12-190256","article-title":"Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia","volume":"113","author":"Chen","year":"2009","journal-title":"Blood"},{"key":"2026073105070036000_bib17","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/leu.2010.290","article-title":"The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine","volume":"25","author":"Walsby","year":"2011","journal-title":"Leukemia"},{"key":"2026073105070036000_bib18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41416-023-02274-2","article-title":"In silico enhancer mining reveals SNS-032 and EHMT2 inhibitors as therapeutic candidates in high-grade serous ovarian cancer","volume":"129","author":"Quintela","year":"2023","journal-title":"Br J Cancer"},{"key":"2026073105070036000_bib19","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41419-021-04344-w","article-title":"Transcriptional inhibition by CDK7\/9 inhibitor SNS-032 suppresses tumor growth and metastasis in esophageal squamous cell carcinoma","volume":"12","author":"Zeng","year":"2021","journal-title":"Cell Death Dis"},{"key":"2026073105070036000_bib20","doi-asserted-by":"crossref","first-page":"112888","DOI":"10.1016\/j.biopha.2022.112888","article-title":"Inhibition of CDK7-dependent transcriptional addiction is a potential therapeutic target in synovial sarcoma","volume":"149","author":"Li","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"2026073105070036000_bib21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12943-019-1070-7","article-title":"Transcriptional inhibition by CDK7\/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma","volume":"18","author":"Zhang","year":"2019","journal-title":"Mol Cancer"},{"key":"2026073105070036000_bib22","doi-asserted-by":"crossref","first-page":"740","DOI":"10.18632\/oncotarget.27928","article-title":"Prognostic and therapeutic value of the Hippo pathway, RABL6A, and p53-MDM2 axes in sarcomas","volume":"12","author":"Desai","year":"2021","journal-title":"Oncotarget"},{"key":"2026073105070036000_bib23","doi-asserted-by":"crossref","first-page":"e9889","DOI":"10.15252\/emmm.201809889","article-title":"Requirement for YAP1 signaling in myxoid liposarcoma","volume":"11","author":"Trautmann","year":"2019","journal-title":"EMBO Mol Med"},{"key":"2026073105070036000_bib24","doi-asserted-by":"crossref","first-page":"19704","DOI":"10.1038\/s41598-019-56247-8","article-title":"Prevalence of the Hippo effectors YAP1\/TAZ in tumors of soft tissue and bone","volume":"9","author":"Isfort","year":"2019","journal-title":"Sci Rep"},{"key":"2026073105070036000_bib25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/1479-5876-11-259","article-title":"A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies","volume":"11","author":"Nemunaitis","year":"2013","journal-title":"J Transl Med"},{"key":"2026073105070036000_bib26","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/cncr.22609","article-title":"Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial","volume":"109","author":"Dileo","year":"2007","journal-title":"Cancer"},{"key":"2026073105070036000_bib27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1158\/1078-0432.CCR-14-1592","article-title":"A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study","volume":"21","author":"Moreno","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026073105070036000_bib28","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1093\/annonc\/mdw281","article-title":"Phase II study of MLN8237 (Alisertib) in advanced\/metastatic sarcoma","volume":"27","author":"Dickson","year":"2016","journal-title":"Ann Oncol"},{"key":"2026073105070036000_bib29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1158\/1535-7163.MCT-16-0235","article-title":"Combinatorial drug screening identifies Ewing sarcoma-specific sensitivities","volume":"16","author":"Radic-Sarikas","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"2026073105070036000_bib30","doi-asserted-by":"crossref","first-page":"7941","DOI":"10.1038\/s41467-024-52067-1","article-title":"Cellular origin and clonal evolution of human dedifferentiated liposarcoma","volume":"15","author":"Gruel","year":"2024","journal-title":"Nat Commun"},{"key":"2026073105070036000_bib31","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/s41588-022-01177-x","article-title":"The evolutionary dynamics of extrachromosomal DNA in human cancers","volume":"54","author":"Lange","year":"2022","journal-title":"Nat Genet"},{"key":"2026073105070036000_bib32","doi-asserted-by":"crossref","first-page":"13003","DOI":"10.3390\/ijms252313003","article-title":"High-throughput drug screening in chondrosarcoma cells identifies effective antineoplastic agents independent of IDH mutation","volume":"25","author":"Li","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026073105070036000_bib33","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.3390\/cancers12123589","article-title":"Beyond the influence of IDH mutations: exploring epigenetic vulnerabilities in chondrosarcoma","volume":"12","author":"Venneker","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026073105070036000_bib34","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1186\/s12885-019-5681-6","article-title":"Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma","volume":"19","author":"Berlow","year":"2019","journal-title":"BMC Cancer"},{"key":"2026073105070036000_bib35","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1158\/1541-7786.MCR-22-0588","article-title":"Interdependence of SS18-SSX-driven YAP1 and beta-catenin activation in synovial sarcoma","volume":"21","author":"Isfort","year":"2023","journal-title":"Mol Cancer Res"},{"key":"2026073105070036000_bib36","first-page":"4570","article-title":"Insulin-like growth factor I receptor-mediated circuit in Ewing\u2019s sarcoma\/peripheral neuroectodermal tumor: a possible therapeutic target","volume":"56","author":"Scotlandi","year":"1996","journal-title":"Cancer Res"},{"key":"2026073105070036000_bib37","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.ccell.2018.05.002","article-title":"The SS18-SSX fusion oncoprotein hijacks BAF complex targeting and function to drive synovial sarcoma","volume":"33","author":"McBride","year":"2018","journal-title":"Cancer Cell"},{"key":"2026073105070036000_bib38","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.molcel.2022.03.019","article-title":"The FUS::DDIT3 fusion oncoprotein inhibits BAF complex targeting and activity in myxoid liposarcoma","volume":"82","author":"Zullow","year":"2022","journal-title":"Mol Cell"},{"key":"2026073105070036000_bib39","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1096\/fasebj.31.1_supplement.178.10","article-title":"CDK 7\/9 inhibition amplifies mithramycin\u2019s suppression of Ewing sarcoma cell proliferation","volume":"31","author":"Flores","year":"2017","journal-title":"FASEB J"},{"key":"2026073105070036000_bib40","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2009.26.1347","article-title":"Phase I and pharmacologic study of SNS-032, a potent and selective CDK2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma","volume":"28","author":"Tong","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026073105070036000_bib41","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1182\/blood.V112.11.3178.3178","article-title":"A phase 1 trial of SNS-032, a potent and specific CDK 2, 7 and 9 inhibitor, in chronic lymphocytic leukemia and multiple myeloma","volume":"112","author":"Wierda","year":"2008","journal-title":"Blood"},{"key":"2026073105070036000_bib42","doi-asserted-by":"crossref","first-page":"B159","DOI":"10.1158\/1535-7163.TARG-23-B159","article-title":"Abstract B159: a first-in-human study of CDK9 inhibitor KB-0742 demonstrates evidence of tolerability and clinical activity","volume":"22","author":"Villalona-Calero","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"2026073105070036000_bib43","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.cell.2018.09.051","article-title":"Targeting CDK9 reactivates epigenetically silenced genes in cancer","volume":"175","author":"Zhang","year":"2018","journal-title":"Cell"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0142\/3796560\/crc-26-0142.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/6\/1425\/3803846\/crc-26-0142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/6\/1425\/3803846\/crc-26-0142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:07:15Z","timestamp":1785488835000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/6\/1425\/785836\/Drug-Screening-of-Sarcoma-Cells-Finding-Shared"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0142","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.33129697","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33129694","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33129703","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33129706","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33129700","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32707038","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32707029","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32707035","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32707041","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32707044","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32707032","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33129709","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8542308","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}